(+)-(S)-2-Ethyl-4-methyl-pentansaeure | 56688-15-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (+)-(S)-2-Ethyl-4-methyl-pentansaeure
• 英文别名: (S)-2-ethyl-4-methyl-pentanoic acid；(2S)-2-ethyl-4-methylpentanoic acid
• CAS: 56688-15-4
• 化学式: C₈H₁₆O₂
• 分子量: 144.214
• InChiKey: XTCNGAJYWUIFFB-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (+)-(S)-2-Ethyl-4-methyl-pentansaeure 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 (2S)-ethyl-4-methyl-1-pentanol
  参考文献：
  名称：

  Kirmse,W. et al., Chemische Berichte, 1975, vol. 108, p. 1839 - 1854

  摘要：

  DOI：

文献信息

• Pyrrolidine derivative or salt thereof
  申请人：Hachiya Shunichiro

  公开号：US20090062366A1

  公开（公告）日：2009-03-05

  [Problem] To provide a compound which may be used in treating diseases in which a calcium sensing receptor (CaSR) is concerned, particularly hyperparathyroidism. [Means for Resolution] It was found that novel pyrrolidine derivatives which are characterized by the possession of aminomethyl group substituted with arylalkyl group or the like, or salts thereof, have excellent CaSR agonistic regulatory activity and also have excellent selectivity with CYP2D6 inhibitory activity having a possibility of causing drug interaction. Based on the above, these novel pyrrolidine derivatives are useful as therapeutic agents for treating diseases in which CaSR is concerned (hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like).

  [问题] 提供一种可用于治疗钙敏感受体（CaSR）相关疾病，特别是甲状旁腺功能亢进症的化合物。 [解决方法] 发现了一种新型吡咯烷衍生物，其特征在于具有氨甲基基团，该基团被芳基烷基或类似物取代，或其盐，具有出色的CaSR激动调节活性，并且具有出色的选择性与CYP2D6抑制活性，可能导致药物相互作用。基于以上发现，这些新型吡咯烷衍生物可用作治疗CaSR相关疾病（甲状旁腺功能亢进症，肾性骨营养不良，高钙血症等）的治疗剂。
• Compositions and methods for treating beta-amyloid related diseases
  申请人：American Life Science Pharmaceuticals, Inc.

  公开号：US10022418B2

  公开（公告）日：2018-07-17

  In alternative embodiments the invention provides compositions and methods for ameliorating diseases and conditions having a beta-amyloid component, including Alzheimer's disease (AD), Vascular Dementia (VD), dementia, pre-dementia, Cognitive Dysfunction Syndrome (CDS) and loss of cognition in humans and in non-human animal. In alternative embodiment the invention provides analogs of AB-007 and its acid form E64c (loxistatin), their preparation, and pharmaceutical compositions thereof and methods of making and using same. In alternative embodiments compositions of the invention are deuterated analogs of AB-007 (or E64d) and E64c (or loxistatin). In alternative embodiments compositions of the invention are metabolically blocked forms as compared to AB-007 and loxistatin. In alternative embodiments compositions of the invention are used to ameliorate (including treat, slow, reverse or prevent) a disease or condition which can be ameliorated by partial or complete inhibition of a cysteine protease, e.g., AD, VD, CDS. The invention also provides alternative dosage forms and formulations for AB-007 and loxistatin, and for compounds of this invention, which can be used e.g., to treat AD, VD and CDS, in humans and in non-human animals.

  在另一个实施方案中，本发明提供了用于改善具有β-淀粉样蛋白成分的疾病和病症的组合物和方法，包括阿尔茨海默病（AD）、血管性痴呆（VD）、痴呆、痴呆前期、认知功能障碍综合征（CDS）以及人类和非人类动物的认知能力丧失。在另一个实施方案中，本发明提供了AB-007及其酸形式E64c（loxistatin）的类似物、它们的制备及其药物组合物以及制造和使用方法。在另一个实施方案中，本发明的组合物是AB-007（或E64d）和E64c（或loxistatin）的氚代类似物。在另一个实施方案中，本发明的组合物与AB-007和loxistatin相比是代谢受阻的形式。在其他实施方案中，本发明的组合物用于改善（包括治疗、减缓、逆转或预防）可通过部分或完全抑制半胱氨酸蛋白酶（如AD、VD、CDS）来改善的疾病或病症。本发明还提供了AB-007和loxistatin以及本发明化合物的替代剂型和制剂，可用于治疗人类和非人类动物的AD、VD和CDS等。
• PYRROLIDINE DERIVATIVE OR SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP1882684B1

  公开（公告）日：2014-12-10
• US7585886B2
  申请人：——

  公开号：US7585886B2

  公开（公告）日：2009-09-08
• US8030279B2
  申请人：——

  公开号：US8030279B2

  公开（公告）日：2011-10-04